Aloracetam

Aloracetam
Clinical data
ATC code
  • none
Legal status
Legal status
  • US: Unscheduled Not FDA approved
Identifiers
IUPAC name
  • N-[2-(3-Formyl-2,5-dimethylpyrrol-1-yl)ethyl]acetamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC11H16N2O2
Molar mass208.261 g·mol−1
3D model (JSmol)
SMILES
  • CC1=CC(=C(N1CCNC(=O)C)C)C=O
InChI
  • InChI=1S/C11H16N2O2/c1-8-6-11(7-14)9(2)13(8)5-4-12-10(3)15/h6-7H,4-5H2,1-3H3,(H,12,15) checkY
  • Key:ZUQSGZULKDDMEW-UHFFFAOYSA-N checkY
  (verify)

Aloracetam (INN) is a drug described as a nootropic which is closely related to, but technically not of (as it lacks a pyrrolidone ring), the racetam family of compounds.[1][2][3] It was studied by Aventis for the treatment of Alzheimer's disease,[4] but was never marketed.

See also

References

  1. ↑ "The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" (PDF). World Health Organization. 2011. Retrieved 22 May 2015.
  2. ↑ George CF (7 July 1998). Drug Therapy in Old Age. Wiley. ISBN 978-0-471-94149-1.
  3. ↑ Ganellin CR, Triggle DJ (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 615–. ISBN 978-0-412-46630-4.
  4. ↑ Fischer F, Matthisson M, Herrling P (2004). "List of drugs in development for neurodegenerative diseases". Neuro-Degenerative Diseases. 1 (1): 50–70. doi:10.1159/000077879. PMID 16908974.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.